Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

AG Edwards Cut Vasogen to Hold from Buy


AG Edwards downgraded Vasogen (VSGN) to hold from buy, citing disappointing results from the company's trial of its heart disease treatment technology Celacade.

Analyst Kevin McDevitt says the trial unambiguously failed. While the Celacade technology treatment did contribute to an intriguing reduction in C-reactive protein (CPR), a widely recognized marker of systemic inflammation associated with increased heart failure, it is not clear that the reduction is sufficient to have meaningful clinical effect, the analyst says. The overall lack of treatment effect in the recent trial leaves McDevitt unwilling to recommend adding money to Vasogen at this time.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus